Afşin, Emine2024-09-252024-09-2520222147-2475https://doi.org/10.5505/respircase.2022.32704https://search.trdizin.gov.tr/tr/yayin/detay/535582https://hdl.handle.net/20.500.12491/16390Although there have been many studies determining\rthe occurrence of post-COVID pulmonary fibrosis\rand thromboembolism, there are a limited number of\rstudies and case reports in literature on the development\rof bronchiectasis. The present study presents a\rcase of bronchiectasis sequel in the post-COVID 11th\rmonth. A 49-year-old male, non-smoker with diabetes\rmellitus and hypertension was admitted with exertional\rdyspnea. The patient had been followed up in\rthe hospital 11 months earlier for 1.5 months with\rsevere COVID-19 pneumonia and respiratory failure\rfor which he was treated with Favipiravir, pulse\rmethylprednisolone and broad-spectrum antibiotics.\rThere was no need for invasive mechanical ventilation,\rand no secondary bacterial infection was detected.\rCompared to the previous CT, a chest CT\rrevealed that bronchiectasis had persisted despite the\rdisappearance of fibrotic changes. In the coming\ryears, one of the first questions raised regarding the\retiology of bronchiectasis may be the patient’s\rCOVID-19 history.eninfo:eu-repo/semantics/openAccessArticle10.5505/respircase.2022.32704112112115535582